Published on 30 Apr 2024 on Simply Wall St. via Yahoo Finance
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This...
Last week, you might have seen that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its first-quarter result to the market. The early response was not positive, with shares down 8.2% to US$82.13 in the past week. Revenues were US$649m, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$0.46, an impressive 41% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Check out our latest analysis for BioMarin Pharmaceutical
